A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.

Trial Details

NCT ID
NCT05456256
Phase
PHASE2
Sponsor
Lantern Pharma Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • LP-300
  • Pemetrexed
  • Carboplatin
Locations (sample)
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Fountain Valley, California, United States|33.70918,-117.95367
  • Los Alamitos, California, United States|33.80307,-118.07256
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Patients with confirmed histopathological diagnosis of inoperable advanced (Stage III or IV) primary adenocarcinoma (including bronchioalveolar cel…
  • Locally advanced inoperable or metastatic lung cancer.
  • Patients must be never smokers: a never smoker is an adult who has never smoked, or who has smoked less than 100 cigarettes (or equivalent in other…
  • Patients who have received systemic treatment with tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer but have experienced disease pr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →